<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Human Genetics</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D3E3D133-1E85-47C0-8DDB-D90CB8795ED7"><gtr:id>D3E3D133-1E85-47C0-8DDB-D90CB8795ED7</gtr:id><gtr:firstName>Che</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Connon</gtr:surname><gtr:orcidId>0000-0001-8264-6531</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FK011111%2F2"><gtr:id>54593E32-27AA-419D-B719-C648A95ED0F5</gtr:id><gtr:title>Investigation of optimal gel conditions for stem cell preservation at room temperature and scaling up of selected methodology</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/K011111/2</gtr:grantReference><gtr:abstractText>For numerous reasons (financial, resource, scientific etc) the centres of excellence responsible for the preparation/manufacture (cell banking, growth, culture, purity and QA etc) of the Living Biologic (LB) in any Regenerative Therapeutic (RT) are geographically separated to that of the point of use. Therefore, a major challenge is to deliver to the clinic the LB in a validated, quality, 'fit for purpose' form. Across the global market place there is a pressing need to retain the key LB characteristic for at least several days to one week. Although suitable for longer term banking, Cryofreezing for the final product is not an option due to the acknowledged negative effects on the LB. As important, the system needs to be simple, rapid and easy to use at the point of care in order to ease uptake by the clinician. Our recent BRIC enabling grant has shown that an alginate gel cell encapsulation system meets many of these needs. We have a growing body of evidence that demonstrates it is effective at preserving a number of cell types (including stem cells) over extended periods in room temperature conditions. However, further research is needed to fully understand how it works and demonstrate that the technology can be implemented in an industrial setting (i.e. scalable).</gtr:abstractText><gtr:technicalSummary>Successful outcome from this project will significantly advance regenerative medicine product development as it will solve the control of distribution/thawing/administration of these complex cellular medicines. Implementing such a step-change in the way cell therapies are distributed will open up novel opportunities and encourage big-pharma's interest in the sector (as a major bottleneck in the product value-chain is reduced).
There is currently an unmet need. Our solution - a simple hydrogel capable of encapsulating and holding stem cells in suspension for up to 1 week at room temperature and atmospheric carbon dioxide. Therefore no need for complicated freezing/thawing systems or the inconvenience of shipping at low temperatures.
With the assistance of chemical engineers we will explore the manufacturing process of hydrogels for stem cell encapsulation in biopolymers with controlled porosity and mechanical properties using an aqueous-in-oil emulsification approach (in which the Co-I is a leading expert). Parallel to this we will investigate the underlying mechanisms that allows for the excellent preservation of stem cells at room temperature once encapsulated within a biopolymer hydrogel. Building upon our exciting (BRIC enabling funded) proof-of-concept results, which have demonstrated the potential of this technology in the regenerative medicine field, we aim to explore its application in commercial settings with the collaboration of BRIC members.</gtr:technicalSummary><gtr:potentialImpactText>The proposed programe of work fits within the BRIC Industry priority research area &amp;quot;Bioprocessing research for cellular products&amp;quot;.
As the proposal will investigate the use of marine alage in the bioprocessing of cellular products is also closely aligned to the BBSRC Industrial Biotechnology and Bioenergy Highlight Notice 1. However we have not indicated this within the clasification of the proposal.

The market demand for an innovative solution to shipping cell therapeutic products is significant and is expected to grow annually in the mid-term. The recent UK Remedi grant reported that the cell therapy sector has increased significantly over the last five years - composed of 138 primary firms and 49 secondary firms. 
Therefore the most immediate beneficiaries will be regenmed SMA's looking for a robust, low cost method to ship cells to academic collaborators, business to business (QA, regulatory bodies etc.) and health-care practitioners. This would be achieved within 2-3 years of the project starting.
The realisation of cell based therapies would move a significant step forward due to the ease and relative low cost to transport of the living biologic, reducing costs for health care providers, ultimately resulting in patient benefit through improved quality of life and health. This would be achieved within 4-8 years of the project starting.
The capability to move cells around without the need for cold storage would open up new areas for the application of cells. Such areas might be on the battle field. We estimate (using our current hydrogel formulations) that enough red blood cells for an emergency blood transfusion could be encapsulated within 330ml flask. If cryo-storage can be combined with ambient storage (to be explored within work package 3) personal blood transfusion kits could be stored cryogenically (eg Camp Bastion) then issued to troops to be kept with them for a week or more. Currently the rule of thumb is that for each 24 hours at room temperature (ie 25 *C) red blood cells lose about a week's worth of refrigerated storage. It may be possible to improve this dramatically.
Other beneficiaries may include companies of government bodies that use cell based assays. Currently this type of assay requires the use of standard aseptic technique (safety cabinet, clean equipment, specialised knowledge etc). However by encapsulating cells it is possible that certain assays could be completed in the field (as the cells remain aseptic within the gel). One example could be environmental toxicity testing using a specific cell viability as an end point which would be assessed colormetrically in the field.
Importantly the propsal will have significant impact upon our understanding of the bioprocessing of materials with cells pre-encapsulated. This area has previously been given little consideration.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>451326</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Stem Cell bandage press coverage</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0E56F3C5-90D9-48FD-AD80-B338571A5026</gtr:id><gtr:impact>Press release on stem cell bandages picked up by local (TV/radio) National (print) and international (websites). Led to commercial interest in product</gtr:impact><gtr:outcomeId>56d71269e4b944.18274731</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbsrc.ac.uk/news/health/2016/160129-pr-seaweed-solution-to-stem-cell-transport/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Defence medical sciences - challenge 2.</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Defence Science &amp; Technology Laboratory (DSTL)</gtr:fundingOrg><gtr:fundingRef>CDE38047</gtr:fundingRef><gtr:id>8E118DDC-77F8-411D-B09F-D3B1BB530B18</gtr:id><gtr:outcomeId>56d70ec4e550b5.59446366</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Enduring challenge competition</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Defence Science &amp; Technology Laboratory (DSTL)</gtr:fundingOrg><gtr:fundingRef>CDE41041</gtr:fundingRef><gtr:id>68E7A43C-00BD-46AC-813D-95C0B0464CE4</gtr:id><gtr:outcomeId>56d70f21892f67.59294663</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>World wide academic advancement, impact published on BBSRC website; Short-listed for Innovator of the Year 2014; trained biologist PDRA in hydrogel chemistry for tissue engineering; developed innovative technology in stem cell storage and cell based assays; collaborating with cell-based therapy company; communicated with cell therapy catapult.
Licensing agreement with veterinary cell therapy company
MTA with international companies Athersys, American cryostem</gtr:description><gtr:firstYearOfImpact>2014</gtr:firstYearOfImpact><gtr:id>291BA3AE-9D25-4836-8928-E14C29F7D0C8</gtr:id><gtr:impactTypes/><gtr:outcomeId>56d86c8bab3188.83962485</gtr:outcomeId><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to hydrogels which may be used to encapsulate or entrap live cells. The invention further relates to methods for transporting live cells which are encapsulated or entrapped within hydrogels from a first location to a second location. The invention further relates to method of treating a wound, disease or tissue injury, e.g. an ocular injury or a damaged ocular surface in a subject using a hydrogel comprising corneal stem cells. The hydrogels used in such methods may be ones which have been transported from a first location to a second location.</gtr:description><gtr:grantRef>BB/K011111/2</gtr:grantRef><gtr:id>4C1D1CF1-BD10-4EAA-A119-052CC418E098</gtr:id><gtr:impact>Spin-out company from Newcastle University is due April 2017</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58b443c8241299.95543487</gtr:outcomeId><gtr:patentId>WO2012127224</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>TRANSPORT OF CELLS IN HYDROGELS</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>We have discovered that fat derived stem cells can be stored for two weeks at ambient temperature whilst retaining their differentiation capabilities. We have found that cell attachment is temperature sensitive. we have found that cell storage in hydrogel is suited to bioprocessing using bead encapsulation. We have found that cells following storage maintain a dose dependent effect on wound healing (increased closure using starch assay)</gtr:description><gtr:exploitationPathways>Our findings have significant implications for the future of cell and tissue printing, our technology facilities the use of a cell printing cartridge that can be stored at room temperature before use allowing cell printing to gain much larger target audience i.e. one that does not have to have cell culture facilities. The technology also facilities the development of cell based assess outside of normal operating conditions such as in a war-zone (airborne toxicity tests). We have developed a prototype stem cell based wound dressing for military purposes</gtr:exploitationPathways><gtr:id>96ED27EA-4765-43C5-AC25-32BC743EBA84</gtr:id><gtr:outcomeId>56d86bbbded882.88247722</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.bbsrc.ac.uk/news/health/2016/160129-pr-seaweed-solution-to-stem-cell-transport/</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Participating in development of new/revised MRC Regen Med grant application. Grant is now shorter and more focussed</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>767AA7A3-C116-49A8-80A1-F3F85BAB765D</gtr:id><gtr:outcomeId>58a5ccf08932d6.14773535</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>https://www.mrc.ac.uk/funding/browse/biomedical-catalyst-rmrc/biomedical-catalyst-regenerative-medicine-research-committee-july-2017/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Stem cell bandage. A hydrogel containing human adipose derived stem cells that can be stored for 2 weeks at 4 degrees C then applied to a superficial wound to speed up wound closure and/or prevent scarring. works via paracrine release from entrapped stem cells.</gtr:description><gtr:id>265B416E-C786-4667-A90B-3C6C92589845</gtr:id><gtr:impact>developing own business to support this invention</gtr:impact><gtr:outcomeId>56d714a8c39570.55867748</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Stem cell bandage</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5EEDF575-F2D8-4C5F-AEB2-026ACFABB647</gtr:id><gtr:title>Keeping cells in their place: the future of stem cell encapsulation.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cace868a2932dad402859863e99ca6ba"><gtr:id>cace868a2932dad402859863e99ca6ba</gtr:id><gtr:otherNames>Swioklo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn><gtr:outcomeId>585d3a21e3d0f1.69928964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C996D000-6965-4904-8F97-796E445CC09B</gtr:id><gtr:title>Alginate-Encapsulation for the Improved Hypothermic Preservation of Human Adipose-Derived Stem Cells.</gtr:title><gtr:parentPublicationTitle>Stem cells translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cace868a2932dad402859863e99ca6ba"><gtr:id>cace868a2932dad402859863e99ca6ba</gtr:id><gtr:otherNames>Swioklo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2157-6564</gtr:issn><gtr:outcomeId>56d70cb4b51b83.11869307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B2468A5-6FCC-48D5-AB5E-219EA6CB70E2</gtr:id><gtr:title>Process parameters for the high-scale production of alginate-encapsulated stem cells for storage and distribution throughout the cell therapy supply chain</gtr:title><gtr:parentPublicationTitle>Process Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cace868a2932dad402859863e99ca6ba"><gtr:id>cace868a2932dad402859863e99ca6ba</gtr:id><gtr:otherNames>Swioklo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58a5a8ae3051b2.10746728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2F1B535-2D6D-4BF0-9032-08A7E69B6830</gtr:id><gtr:title>Alginate hydrogels for the 3D culture and therapeutic delivery of cells</gtr:title><gtr:parentPublicationTitle>RSC Soft Matter</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d985b9fbf58718c6f3a949d0d785238"><gtr:id>8d985b9fbf58718c6f3a949d0d785238</gtr:id><gtr:otherNames>Wright B.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54201b191b2703.22921899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB6A118F-BC54-448D-A4F8-C5A8E32E9105</gtr:id><gtr:title>Hybrid membrane biomaterials from self-assembly in polysaccharide and peptide amphiphile mixtures: controllable structural and mechanical properties and antimicrobial activity</gtr:title><gtr:parentPublicationTitle>RSC Advances</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb145344eaa7cf0c2033992c0c10ec6c"><gtr:id>eb145344eaa7cf0c2033992c0c10ec6c</gtr:id><gtr:otherNames>Castelletto V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58a5aab08bd4a7.97859717</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6900CAB2-6BCF-4870-8771-40F711C94B98</gtr:id><gtr:title>Alginate hydrogels for the 3D culture and therapeutic delivery of cells</gtr:title><gtr:parentPublicationTitle>RSC Soft Matter</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cf26e7440f6b83d88022bec93d2a034"><gtr:id>6cf26e7440f6b83d88022bec93d2a034</gtr:id><gtr:otherNames>Wright, B.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>58a5a8aecd4e48.70185264</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/K011111/2</gtr:identifier></gtr:identifiers><gtr:projectHierarchy><gtr:parents><gtr:parent><gtr:id>0747FB25-2AE2-46C5-A567-29275C28C907</gtr:id><gtr:grantRef>BB/K011111/1</gtr:grantRef><gtr:amount>579830.8</gtr:amount><gtr:start>2013-10-31</gtr:start><gtr:end>2014-08-31</gtr:end><gtr:children><gtr:child rel="Transfer"><gtr:id>54593E32-27AA-419D-B719-C648A95ED0F5</gtr:id><gtr:grantRef>BB/K011111/2</gtr:grantRef><gtr:amount>451326.0</gtr:amount><gtr:start>2014-09-01</gtr:start><gtr:end>2016-10-31</gtr:end><gtr:children/></gtr:child></gtr:children></gtr:parent></gtr:parents></gtr:projectHierarchy><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>E847DD9B-2053-4BC7-97A9-4213B185C968</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Materials sciences</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>FB535BD0-E265-4C0A-8532-32DCB83A3951</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Tools, technologies &amp; methods</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>BD108981-2A72-4C45-AAC2-425461EB90BE</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomaterials</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>16595C3C-600D-4AD2-B394-16E06F96495F</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Med.Instrument.Device&amp; Equip.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>3493671D-A4CF-4197-90A7-3CCFBE1C0627</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Tools for the biosciences</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>